Neuroprotective effects of furopyrazole derivative of benzylindazole analogs on C2 ceramide-induced apoptosis in cultured cortical neurons

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 12, 2009, Pages 3225-3228

  Lin, Yi Chien ^a   Chou, Li Chen ^a   Chen, Sheng Chih ^a   Kuo, Sheng Chu ^a   Huang, Li Jiau ^a   Gean, Po Wu ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Benzylindazole analogs; Ceramide; Neurodegenerative diseases

Indexed keywords

BENZYLINDAZOLE DERIVATIVE; CERAMIDE; FUROPYRAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; METHANOL DERIVATIVE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN CELL; DEGENERATIVE DISEASE; DRUG STRUCTURE; NEUROPROTECTION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CEREBRAL CORTEX; ENZYME INHIBITORS; HUMANS; INDAZOLES; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PYRAZOLES; SPHINGOSINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65749091452     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.101     Document Type: Article

References (24)

1. Friebe A., and Koesling D. Mol. Pharmacol. 53 (1998) 123
2. Chien W.L., Liang K.C., Teng C.M., Kuo S.C., Lee F.Y., and Fu W.M. Mol. Pharmacol. 63 (2003) 1322
3. Chien W.L., Liang K.C., Teng C.M., Kuo S.C., Lee F.Y., and Fu W.M. Eur. J. Neurosci. 21 (2005) 1679
4. Mayer B., and Koesling D. Trends Pharmacol. Sci. 22 (2001) 546
5. Koesling D., Russwurm M., Mergia E., Mullershausen F., and Friebe A. Neurochem. Int. 45 (2004) 813
6. Fiscus R.R. NeuroSignals 11 (2002) 175
7. Bredt D.S. Mol. Pharmacol. 63 (2003) 1206
8. Ha K.S., Kim K.M., Kwon Y.G., Bai S.K., Nam W.D., Yoo Y.M., Kim P.K., Chung H.T., Billiar T.R., and Kim Y.M. FASEB J. 17 (2003) 1036
9. Takuma K., Phuagphong P., Lee E., Enomoto R., Mori K., Baba A., and Matsuda T. Jpn. J. Pharmacol. 89 (2002) 64
10. Mathias S., Pena L.A., and Kolesnick R.N. Biochem. J. 335 (1998) 465
11. Toman R.E., Movsesyan V., Murthy S.K., Milstien S., Spiegel S., and Faden A.I. J. Neurosci. Res. 68 (2002) 323
12. Buccoliero R., and Futerman A.H. Pharmacol. Res. 47 (2003) 409
13. Ruvolo P.P. Pharmacol. Res. 47 (2003) 383
14. Stoica B.A., Movsesyan V.A., Lea IV P.M., and Faden A.I. Mol. Cell. Neurosci. 22 (2003) 365
15. Zhou H., Summers S.A., Birnbaum M.J., and Pittman R.N. J. Biol. Chem. 273 (1998) 16568
16. Goswami R., and Dawson G. J. Neurosci. Res. 60 (2000) 141
17. Stoica B.A., Movsesyan V.A., Knoblach S.M., and Faden A.I. Mol. Cell. Neurosci. 29 (2005) 355
18. Ariga T., Jarvis W.D., and Yu R.K. J. Lipid Res. 39 (1998) 1
19. Chou L.C., Huang L.J., Yang J.S., Lee F.Y., Teng C.M., and Kuo S.C. Bioorg. Med. Chem. 15 (2007) 1732
20. 2). Cytosine arabinoside (4 μM) was added at day 1 in vitro (DIV 1) after plating to prevent the proliferation of non-neuronal cells. All experiments were performed on cultures at 4 days in vitro (DIV 4). Cell survival was evaluated by MTT reduction assays. Cells were incubated with MTT for 2 h at 37 °C. The absorption value at wavelength of 570 nm was determined with an ELISA plate reader. Data were presents as the percentage of survival relative to vehicle-treated control culture. All measurements were performed in triplicate and each experiment was repeated at least three times.
21. For Hoechst staining, cells grown on coverslips were washed 1× PBS and then fixed with 4% paraformaldehyde in PBS for 10 min. After several washes with 1× PBS, 2.5 μg/ml DNA dye Hoechst 33,258 (bis-benzimide, Sigma) was applied to each coverslip. The samples were protected from light and incubated under room temperature for 10 min. After one wash 1× PBS, nuclei were visualized using a fluorescent microscope. Fluorescence of the soluble DNA (apoptotic) fragments was measured in a Varian Fluorometer at excitation wavelength of 365 nm and emission wavelength 460 nm.
22. Hetman M., and Gozdz A. Eur. J. Biochem. 271 (2004) 2050
23. Pan S.L., Guh J.H., Chang Y.L., Kuo S.C., Lee F.Y., and Teng C.M. Cardiovasc. Res. 61 (2004) 152
24. Garthwaite G., Goodwin D.A., Neale S., Riddall D., and Garthwaite J. Mol. Pharmacol. 61 (2002) 97